![Atul Saran](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Atul Saran
Plus aucun poste en cours
Profil
Atul Saran is Chief Executive Officer & Director at IntegerBio, Inc. since 2023.
Director at Emergent Product Development UK Ltd. since 2017.
Secretary & Director at Emergent Countermeasures International Ltd. since 2018.
Member of The District of Columbia Bar.
Formerly Director at Inotek Pharmaceuticals Corp., Arriva Pharmaceuticals, Inc., and VentiRx Pharmaceuticals, Inc. Independent Director at Xencor, Inc. from 2011 to 2014.
Vice President-Corporate Development & Ventures at MedImmune LLC from 2003 to 2014.
Vice President-Corporate Development & Ventures at AstraZeneca PLC from 2013 to 2014.
SVP-Corporate Development & Ventures at MedImmune Ventures, Inc. Senior Vice President & General Counsel at MacroGenics, Inc. from 2014 to 2017.
Associate Attorney at Hogan & Hartson LLP.
Executive VP, Chief Strategy & Development Officer at Emergent BioSolutions, Inc. from 2022 to 2023.
Member of California State Bar Association.
Education includes undergraduate degree from Stanford University, MBA from MIT Sloan School of Management, and graduate degree from the University of Illinois College of Law.
Postes actifs de Atul Saran
| Sociétés | Poste | Début |
|---|---|---|
The District of Columbia Bar
 The District of Columbia Bar Miscellaneous Commercial ServicesCommercial Services Provides legal services | Corporate Officer/Principal | - |
Emergent Product Development UK Ltd.
 Emergent Product Development UK Ltd. Pharmaceuticals: MajorHealth Technology Develops oral vaccines for typhoid, travelers diarrhea, hepatitis B and anthrax | Directeur/Membre du Conseil | 20/12/2017 |
Emergent Countermeasures International Ltd.
 Emergent Countermeasures International Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical preparations | Directeur/Membre du Conseil | 18/12/2018 |
Anciens postes connus de Atul Saran
| Sociétés | Poste | Fin |
|---|---|---|
| EMERGENT BIOSOLUTIONS INC. | Conseiller Juridique Général | 01/03/2022 |
| MACROGENICS, INC. | Conseiller Juridique Général | 01/05/2017 |
California State Bar Association | Corporate Officer/Principal | 15/05/2014 |
| XENCOR, INC. | Directeur/Membre du Conseil | 23/01/2014 |
| ASTRAZENECA PLC | Corporate Officer/Principal | 01/01/2014 |
Formation de Atul Saran
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
77
Relations au 1er degré
17
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 17 |
|---|---|
MedImmune LLC
 MedImmune LLC Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
AstraZeneca PLC
 AstraZeneca PLC Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Inotek Pharmaceuticals Corp.
 Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Engages in the development, discovery and commercialization of therapies for glaucoma and other diseases of the eye | Health Technology |
Arriva Pharmaceuticals, Inc.
 Arriva Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops anti-inflammatory therapies for treating respiratory diseases | Health Technology |
MedImmune Ventures, Inc.
 MedImmune Ventures, Inc. Investment ManagersFinance MedImmune Ventures invests in private biotechnology companies located across the globe primarily in North America. The firm focuses on healthcare sectors such as molecules, vaccines, pharmaceutical technologies, medical devices, diagnostics, imaging and healthcare IT. The firm provides financing for seed, early, later and mezzanine stage capital requirements with an investment size ranging from USD 5 - USD 10 million per round. It acts as a lead investor and takes an active role on the board of directors. | Finance |
Xencor, Inc.
 Xencor, Inc. BiotechnologyHealth Technology Develops therapeutics to treat autoimmune and allergic diseases, cancer and other conditions | Health Technology |
VentiRx Pharmaceuticals, Inc.
 VentiRx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel medicines | Health Technology |
Stanford University
 Stanford University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
MacroGenics, Inc.
 MacroGenics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes antibody-based therapeutics for the treatment of cancer | Health Technology |
Hogan & Hartson LLP
 Hogan & Hartson LLP Miscellaneous Commercial ServicesCommercial Services Provides legal services | Commercial Services |
Emergent BioSolutions, Inc.
 Emergent BioSolutions, Inc. Pharmaceuticals: MajorHealth Technology Manufactures biopharmaceutical products | Health Technology |
Emergent Product Development UK Ltd.
Emergent Product Development UK Ltd. Pharmaceuticals: MajorHealth Technology Develops oral vaccines for typhoid, travelers diarrhea, hepatitis B and anthrax | Health Technology |
The District of Columbia Bar
The District of Columbia Bar Miscellaneous Commercial ServicesCommercial Services Provides legal services | Commercial Services |
California State Bar Association | |
MIT Sloan School of Management
 MIT Sloan School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Illinois College of Law
 University of Illinois College of Law Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Emergent Countermeasures International Ltd.
Emergent Countermeasures International Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical preparations | Health Technology |
